FluoroPharma Medical, Inc. (FPMI) is focused on developing breakthrough molecular imaging agents for positron emission tomography (PET) and fluorescence imaging. The company's agents will give clinicians the essential tools for the detection and assessment of pathology before clinical manifestations of disease. The market for molecular imaging agents currently exceeds $1.7 billion annually.